Atreca, Inc. (NASDAQ:BCEL) Short Interest Update

Atreca, Inc. (NASDAQ:BCEL) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 148,000 shares, a decline of 45.7% from the February 29th total of 272,700 shares. Based on an average daily trading volume, of 8,350,000 shares, the days-to-cover ratio is presently 0.0 days.

Atreca Trading Down 6.3 %

Shares of BCEL stock opened at $0.08 on Thursday. Atreca has a 1-year low of $0.05 and a 1-year high of $1.35. The company has a market capitalization of $2.97 million, a price-to-earnings ratio of -0.03 and a beta of 1.17. The stock’s fifty day simple moving average is $0.24 and its 200-day simple moving average is $0.24.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BCEL. Charles Schwab Investment Management Inc. purchased a new position in Atreca in the first quarter valued at about $26,000. IHT Wealth Management LLC purchased a new position in Atreca in the first quarter valued at about $41,000. Dynamic Technology Lab Private Ltd purchased a new position in Atreca in the first quarter valued at about $41,000. Advisor Group Holdings Inc. grew its stake in Atreca by 111.8% in the first quarter. Advisor Group Holdings Inc. now owns 16,573 shares of the company’s stock valued at $52,000 after purchasing an additional 8,750 shares in the last quarter. Finally, ExodusPoint Capital Management LP purchased a new position in Atreca in the fourth quarter valued at about $89,000. Hedge funds and other institutional investors own 37.47% of the company’s stock.

Atreca Company Profile

Atreca, Inc, a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform.